Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Income (2021 - 2025)

Historic Net Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.0 million.

  • InMed Pharmaceuticals' Net Income rose 2123.48% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.7 million, marking a year-over-year increase of 306.04%. This contributed to the annual value of -$8.2 million for FY2025, which is 633.94% down from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Net Income is -$2.0 million, which was up 2123.48% from -$1.7 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Net Income registered a high of -$336591.0 during Q2 2023, and its lowest value of -$7.9 million during Q2 2022.
  • For the 5-year period, InMed Pharmaceuticals' Net Income averaged around -$2.6 million, with its median value being -$2.1 million (2022).
  • As far as peak fluctuations go, InMed Pharmaceuticals' Net Income surged by 9572.31% in 2023, and later plummeted by 47356.58% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Net Income stood at -$4.3 million in 2021, then skyrocketed by 51.01% to -$2.1 million in 2022, then grew by 29.55% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025.
  • Its Net Income stands at -$2.0 million for Q4 2025, versus -$1.7 million for Q3 2025 and -$1.8 million for Q2 2025.